Metabonomic Profiling of Bladder Cancer

Chan, Eric Chun Yong; Pasikanti, Kishore Kumar; Hong, Yanjun; Ho, Paul C.; Mahendran, Ratha; Mani, Lata Raman Nee; Chiong, Edmund; Esuvaranathan, Kesavan

doi:10.1021/pr500966h

Cited by 42 publications

(54 citation statements)

References 195 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Currently, metabolomics has demonstrated its practicality by the identification of BC biomarkers in urine, 15,16 plasma and tissue samples. 17,18 Additionally, metabolic studies in cell culture are highly valuable 19 as they can identify functional biomarkers that represent cellular processes, 20,21 and/or provide insights into the individuality of various cancer cell lines. 22,23 These are essential for a comprehensive understanding of cancer cell biology and to complement clinical studies.…”

Section: Introductionmentioning

confidence: 99%

Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway

et al. 2016

View full text Add to dashboard Cite

Metabolic profiling has great potential to help the diagnosis and prognosis of cancer patients. Fanconi Anemia (FA) tumor suppressor signaling has been instrumental in understanding human-tumorigenesis. However, this instrumental understanding has never been demonstrated at the metabolic level. Here we show that impaired FA signaling can lead cells to exhibit metabolic signatures of tumorigenesis. This is consistent with our original studies of the roles of FA signaling in suppressing non-FA tumorigenesis at functional and genetic levels. Using ultra-performance liquid chromatography-mass spectroscopy and gas chromatography-mass spectrometry, we characterized metabolic alterations in bladder cancer cells carrying an intact or impaired FA pathway. The latter was obtained by ectopically expressing FAVL (FAVL-high), which we previously found to be capable of inactivating FA signaling. 18 metabolites, end products of cell proliferation and/or apoptosis, were significantly different between FAVL-high and -low cells. Methionine, phenylalanine and threonine, resulting from a tumorigenic process, were substantially increased in FAVL-high cells. With this study, we achieved genomic, functional, and metabolomic characterization on roles of FA signaling in the development of human cancer. Furthermore, this study provides novel insights into how to translate FA basic research into strategies for producing effective biomarkers in human cancer diagnosis and prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Investigating potential biomarkers may bring about new breakthroughs in strategies on reducing recurrence and survival rate, similar to the discovery of trastuzumab following studies on the human epidermal growth factor receptor-2 (HER2) studies. Recently, important progress has been made in the biomarker field particularly in new detection techniques in genomics and proteomics (27,28). In bladder cancer, a number of accomplishments were achieved, including the Table II.…”

Section: Discussionmentioning

confidence: 99%

TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer

Hao

Cui

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the clinical significance of TNF receptor-associated factor 6 (TRAF6) expression in urothelial bladder cancer. TRAF6 expression was detected by immunohistochemistry in 126 samples of patients with urothelial bladder cancer. The association between clinicopathological factors and TRAF6 expression was analyzed by χ 2 test. The association between TRAF6 expression, overall survival rate and the recurrence-free survival rate was evaluated in univariate analysis with Kaplan-Meier test and in multivariate analysis with Cox-regression model. In the cohort tested, the rate of high TRAF6 expression was 61.9% (78/126). TRAF6 expression was demonstrated to be significantly associated with positive metastasis (P=0.001) with χ 2 test. Furthermore, TRAF6 expression was demonstrated to be associated with overall survival rate (P=0.016) and recurrence-free survival rate (P=0.016). With Cox-regression model, it was indicate that TRAF6 high expression was an independent predictive factor of poor prognosis (P=0.037) and high recurrence (P=0.011). High TRAF6 expression may predict unfavorable prognosis and high recurrence in urothelial bladder cancer, indicating that TRAF6 may be a potential and promising therapeutic target in urothelial bladder cancer.

show abstract

“…Various studies using mass spectrometric (MS) methods reported promising results for bladder cancer (BCa) detection and separation of invasive BCa from non-invasive BCa (Issaq et al, 2008;Huang et al, 2011;Pasikanti et al, 2013;Chan et al, 2015;Zhou et al, 2016). However, cohort sizes were small in most studies and the effects of renal cancer and bladder inflammation were the major problem in BCa detection (Van et al, 2011).…”

Section: Bladder Cancermentioning

confidence: 99%

Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer

Yang

Lü

Wen

et al. 2017

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy.

show abstract

Metabonomic Profiling of Bladder Cancer

Cited by 42 publications

References 195 publications

Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway

Distinct Metabolic Signature of Human Bladder Cancer Cells Carrying an Impaired Fanconi Anemia Tumor-Suppressor Signaling Pathway

TRAF6 expression is associated with poorer prognosis and high recurrence in urothelial bladder cancer

Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer

Contact Info

Product

Resources

About